Vertex Pharma Says Phase 3 Study Results of Ivacaftor Did Not Meet Primary Endpoint

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX ) today announced data from a Phase 3 study of ivacaftor in 69 people 6 years of age and older with cystic fibrosis (CF) who have the R117H mutation. In the study, the mean absolute treatment difference in the change from baseline in percent predicted FEV[1] between treatment with